NVSNovartis PharmaceuticalsNot started yet
Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.
PIK3CA-Related Overgrowth Spectrum (PROS) · Breast Neoplasms (Including Advanced or Metastatic Breast Cancer With PIK3CA Mutation)
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 51 (planned)
- Started
- Dec 15, 2026
- Main results expected
- Mar 23, 2032
- Fully finished
- Apr 20, 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Measured over: From start of treatment up to 30 days after last dose of study treatment, assessed up to approximately 53 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07679269 · record last updated 2026-09-18 · checked 2026-11-09 15:47 UTC